298 related articles for article (PubMed ID: 16540667)
1. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
[TBL] [Abstract][Full Text] [Related]
2. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
[TBL] [Abstract][Full Text] [Related]
3. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
[TBL] [Abstract][Full Text] [Related]
5. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
7. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
[TBL] [Abstract][Full Text] [Related]
9. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.
Shao H; Cheng HY; Cook RG; Tweardy DJ
Cancer Res; 2003 Jul; 63(14):3923-30. PubMed ID: 12873986
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
12. Impact of EGFR mutation analysis in non-small cell lung cancer.
Yamamoto H; Toyooka S; Mitsudomi T
Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
[TBL] [Abstract][Full Text] [Related]
13. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
Weerasinghe P; Garcia GE; Zhu Q; Yuan P; Feng L; Mao L; Jing N
Int J Oncol; 2007 Jul; 31(1):129-36. PubMed ID: 17549413
[TBL] [Abstract][Full Text] [Related]
15. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Sordella R; Bell DW; Haber DA; Settleman J
Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
[TBL] [Abstract][Full Text] [Related]
19. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes.
Quadros MR; Peruzzi F; Kari C; Rodeck U
Cancer Res; 2004 Jun; 64(11):3934-9. PubMed ID: 15173005
[TBL] [Abstract][Full Text] [Related]
20. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis.
Nomoto K; Tsuta K; Takano T; Fukui T; Fukui T; Yokozawa K; Sakamoto H; Yoshida T; Maeshima AM; Shibata T; Furuta K; Ohe Y; Matsuno Y
Am J Clin Pathol; 2006 Oct; 126(4):608-15. PubMed ID: 16938658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]